Zivo Bioscience, Inc. · OTC:ZIVO
Zivo Bioscience — Investor Presentation (March 2021)
17 slides from Zivo Bioscience's investor presentation, Mar 17, 2021
Slide 1: Transformative Opportunities in Immune Health Therapeutics & Nutrition
Transformative Opportunities in Immune Health Therapeutics & Nutrition March 2021 iCIENCE www.zivobioscience.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended
Slide 3: What do all these global health issues have in common?
What do all these global health issues have in common? Drug-resistant pathogens Autoimmune Disorders Sepsis/Toxic Shock oo, Poultry Coccidiosis Antibiotic residues in dairy products e.Coli contamination Antibiotic-laced meat Bovine Mastitis a Type 1 Diabetes Arthritis Multiple Sclerosis | Necrotic e
Slide 4: What do all these global health issues have in common?
What do all these global health issues have in common? Drug-resistant pathogens Autoimmune Disorders Sepsis/Toxic Shock oo, Poultry Coccidiosis Antibiotic residues in dairy products e.Coli contamination Antibiotic-laced meat Bovine Mastitis a Type 1 Diabetes Arthritis Multiple Sclerosis | Necrotic e
Slide 5: Billions spent on therapeutics, medicines, additives and ingredients
Billions spent on therapeutics, medicines, additives and ingredients Human Market Annualized Spanning years 2017-2020 World Population 1700 C.E. to 2050 C.E. In Billions Antibiotics $40.0B 4.5% CAGR Eubiotics $5.8B 7.3% CAGR Autoimmune $110.0B 4.2% CAGR Antidiabetic $78.7B 6.1% CAGR Immune-related a
Slide 6: Billions spent on therapeutics, medicines, additives and ingredients
Billions spent on therapeutics, medicines, additives and ingredients Poultry Market Annualized Spanning years 2016-2019 Vaccines- $2.0B 6.2% CAGR Phytogenics - $754.0M 7.7% CAGR Eubiotics- $1.6B 8.1% CAGR lonophores $1.2B* 3.2% CAGR *Primarily lonophores Our global food supply is reliant on antimicr
Slide 7: ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc. A new path to optimal health
Slide 8: A two-tiered approach to human and animal immune health
A two-tiered approach to human and animal immune health Bi0te ch wees: Biotechnology Compouhds Coftiplexes Ps os f Ag Tech Algal Biomass Extracts f Agricultural Technology bry Mixes F _s . —,. ‘ Pharma - Biotech Patent-pending immune modulator may create a new class of therapeutics or immune product
Slide 9: Biotech
“Biotech Biotechnolo: igeloay Cell Membrane ZIVO is conducting optimization of a novel immune modulating molecular complex for human and animal therapeutics and regulated immune ‘ytoKines & e products Interior of Immune Cell _
Slide 10: AgTech Algal Biomass
AgTech Algal Biomass Inn at e ‘ Extracts Agricultural Technology Dry Mixes ZIVO Product Claims mu ee Immune & Metabolic Health Adaptive ® BCell ZIVO-sponsored in vitro and in vivo % r reel studies and analyses point toward i = A potentially new superfood 7: = Anovel topical skin health product Activ
Slide 11: What we've accomplished to date
What we've accomplished to date BOE eee SERS Sel Biotechnology _ © Complex Immune Modulating Molecules = TLR-4 immune modulator announced Q4 2019 = Ten (10) patents filed since Q4 2019 = Manufacturing Proof of Concept confirmed Q4 2020 Poultry Digestive Health = Seventeen (17) major in vivo studies
Slide 12: Business Models & Market Verticals
Business Models & Market Verticals Biotech #1 - Poultry Digestive Health IP Licensing/Partnering Models * Discovery Stage Licensing, OR * Discovery Stage Licensing, OR . = Joint Development Agreement (JDA) = Joint Development Agreement Expected Revenue Stream Expected Revenue Stream * Option & Licen
Slide 13: Business Models & Market Verticals
Business Models & Market Verticals 7 y istributi . Corporate Culture Compliance Pilot Outsourced Distribution Marketin Production & IV's a Customers Manufacturing Development & Compliance License Fees Distributor Fees Ingredient Sales Formulated Product Sales A Te h ZIVO intends to outsource product
Slide 14: Leadership Team
Leadership Team Andrew A. Dahl - President and CEO Over 30 years experience in business case development, marketing planning and business development. He brings Fortune 500 rigor and diligence to early- stage life science companies, setting priorities, shaping business models and facilitating resour
Slide 15: Growth Prospects & Comparatives
Growth Prospects & Comparatives ZIVO intends to license its proprietary molecules or bioproducts and look for opportunities to fully monetize its intellectual property portfolio across multiple applications Biotech #1 - Poultry Digestive Health #2 - Porcine Immune Therapeutic/immune Product Comp —__
Slide 16: Where We're Headed — Goals for 2021 and Beyond
Where We're Headed — Goals for 2021 and Beyond Biotech wa. Biotechnology _ © Complex Poultry Digestive Health = Prospective licensing or joint development deal = Continue refinement of poultry product candidates = Productize, commercialize successful market entry Immune Modulating Product = Commerci
Slide 17: In Summary
In Summary Acommon platform in two divergent sectors. Each is primed for growth. Biotech AgTech Biotechnology Agricultural Technology HO, ‘OH oH Ho, " ‘OH ry ° On Ho. al Q 6 A Functional Superfood That Actually Tastes Good °. Therapeutic Innovations ° Sustainable & Responsible Cultivation W071 So °